Artigo Acesso aberto Revisado por pares

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma

2018; AMCP; Volume: 24; Issue: 4 Linguagem: Inglês

10.18553/jmcp.2018.24.4.335

ISSN

2376-1032

Autores

Elyse Swallow, Andrew Messali, Sameer R. Ghate, Evangeline McDonald, Emilie D. Duchesneau, José Ricardo Pérez,

Tópico(s)

Health Systems, Economic Evaluations, Quality of Life

Resumo

When considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment.

Referência(s)